Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry R Kaiser

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Annals of Surgical Oncology|December 2, 2011
Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United StatesPutao Cen, Farzaneh Banki, Lee Cheng, et al.
Cancer Research|June 18, 2003
Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancerTamotsu Kuroki, Francesco Trapasso, Sai Yendamuri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunityEiji Suzuki, Veena Kapoor, H Kam Cheung, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 31, 2004
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic responseMitchell Machtay, Jason H Lee, James P Stevenson, et al.
Annals of Surgery|December 29, 2004
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgeryTomoyuki Tanaka, Peter A Delong, Kunjlata Amin, et al.
The Annals of Thoracic Surgery|December 23, 2006
Cytokine response is lower after lung volume reduction through bilateral thoracoscopy versus sternotomyMichael E Friscia, Jianliang Zhu, Jeffrey W Kolff, et al.
Innovations (Philadelphia, Pa.)|July 26, 2014
One-and-a-half ventricular repair for isolated right ventricle metastatic tumor resection after lobectomy for lung cancerAkira Shiose, Parag Desai, Gerard J Criner, et al.
Anesthesiology|November 2, 2002
Long-term pain and activity during recovery from major thoracotomy using thoracic epidural analgesiaE Andrew Ochroch, Allan Gottschalk, John Augostides, et al.
Annals of Surgical Oncology|April 2, 2008
Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction modelJin Ra, E Carter Paulson, John Kucharczuk, et al.
Cancer Research|November 25, 2003
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapyPeter DeLong, Tomoyuki Tanaka, Robb Kruklitis, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Annals of Surgical Oncology|December 2, 2011
Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United StatesPutao Cen, Farzaneh Banki, Lee Cheng, et al.
Cancer Research|June 18, 2003
Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancerTamotsu Kuroki, Francesco Trapasso, Sai Yendamuri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunityEiji Suzuki, Veena Kapoor, H Kam Cheung, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 31, 2004
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic responseMitchell Machtay, Jason H Lee, James P Stevenson, et al.
Annals of Surgery|December 29, 2004
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgeryTomoyuki Tanaka, Peter A Delong, Kunjlata Amin, et al.
The Annals of Thoracic Surgery|December 23, 2006
Cytokine response is lower after lung volume reduction through bilateral thoracoscopy versus sternotomyMichael E Friscia, Jianliang Zhu, Jeffrey W Kolff, et al.
Innovations (Philadelphia, Pa.)|July 26, 2014
One-and-a-half ventricular repair for isolated right ventricle metastatic tumor resection after lobectomy for lung cancerAkira Shiose, Parag Desai, Gerard J Criner, et al.
Anesthesiology|November 2, 2002
Long-term pain and activity during recovery from major thoracotomy using thoracic epidural analgesiaE Andrew Ochroch, Allan Gottschalk, John Augostides, et al.
Annals of Surgical Oncology|April 2, 2008
Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction modelJin Ra, E Carter Paulson, John Kucharczuk, et al.
Cancer Research|November 25, 2003
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapyPeter DeLong, Tomoyuki Tanaka, Robb Kruklitis, et al.
Pageof 10